Page-1
VICC MEL 1290 Phase 1 Study of the BRAF Inhibitor Dabrafenib... VICC MEL 12100 A Randomized, Open-Label Phase 3 Trial of... VICC MEL 1290 Phase 1 Study of the BRAF Inhibitor Dabrafenib... VICC MEL 1278 Randomized, Phase II Study of MK-3475 versus... VICC MEL 1276 A Phase 1b/2, Multicenter, Open-label Trial to... VICC MEL 1278 Random ized, Phase II Study of MK-3475 versus... VICC PHI 1231 Phase 1/2 Study of PI-3K Inhibition with PX-866... VICC MEL 1230 MEK116513: A Phase III, Randomised, Open-Label... VICC PHI 1231 Phase 1/2 Study of PI-3K Inhibition with PX-866... VICC PHI 1231 Phase 1/2 Study of PI-3K Inhibition with PX-866... VICC MEL 1168 An Open-label Multicenter Phase II Study of... VICC MEL 1081 The High-Dose Aldesleukin (IL-2) "Select"... VICC PHI 1075 A Phase Ib, Open Label, Dose-Escalation, Study... VICC MEL 1036 A Phase II Correlative Clinical Trial of... Click here to print
this page (PDF) Melanoma Flowcharts